Table 3.
Treatment effects on heart rate during the 180 min post-injection period
| Experiment | Treatment | Treatment × Time |
|---|---|---|
| 1. OT dose–response | ||
| (i) Linear trend | F(1,2) = 17.26 | – |
| (ii) Quadratic trend | F(1,2) = 18.45* | – |
| 2A. C25 (5 and 10 mg·kg−1) and OT (1 mg·kg−1) | ||
| (i) VEH versus OT | F(1,3) = 57.03** | F(2.38,7.15) = 7.84* |
| (ii) OT versus C25 (5) + OT | F(1,3) = 4.24 | F(2.67,8.00) = 1.16 |
| (iii) OT versus C25 (10) + OT | F(1,3) = 19.40 | F(2.39,7.16) = 1.17 |
| 2B. C25 (5 and 10 mg·kg−1) and VEH | ||
| (i) VEH versus C25 (5) + VEH | F(1,3) = 20.66* | F(2.90,8.69) = 1.41 |
| (ii) VEH versus C25 (10) + VEH | F(1,3) = 47.06** | F(2.73,8.18) = 1.51 |
| 3A. SR (1 and 10 mg·kg−1) and OT (1 mg·kg−1) | ||
| (i) VEH versus OT | F(1,3) = 126.43** | F(2.27,6.80) = 7.56* |
| (ii) OT versus SR (1) + OT | F(1,3) = 21.78 | F(2.52,7.55) = 10.22** |
| (iii) OT versus SR (10) + OT | F(1,3) = 59.30** | F(2.62,7.86) = 13.03** |
| 3B. SR (1 and 10 mg·kg−1) and VEH | ||
| (i) VEH versus SR (1) + VEH | F(1,3) = 0.32 | F(2.15,6.45) = 0.86 |
| (ii) VEH versus SR (10) + VEH | F(1,3) = 0.09 | F(2.36,7.08) = 1.67 |
| 4. AVP dose–response | ||
| (i) Linear trend | F(1,3) = 84.17** | – |
| (ii) Quadratic trend | F(1,3) = 13.67* | – |
| 5. SR (1 and 10 mg·kg−1) and AVP (0.1 mg·kg−1) | ||
| (i) VEH versus AVP | F(1,3) = 571.38*** | F(2.21,6.63) = 2.98 |
| (ii) AVP versus SR (1) + AVP | F(1,3) = 41.28** | F(2.49,7.46) = 2.22 |
| (iii) AVP versus SR (10) + AVP | F(1,3) = 92.61** | F(2.25,6.76) = 4.72 |
| 6. WAY dose–response | ||
| (i) Linear trend | F(1,3) = 5.23 | – |
| (ii) Quadratic trend | F(1,3) = 12.63* | – |
| 7. C25 (10 mg·kg−1) and WAY (100 mg·kg−1) | ||
| (i) VEH versus WAY | F(1,2) = 19.16 | F(1.96,3.92) = 3.98 |
| (ii) WAY versus C25 + WAY | F(1,2) = 0.09 | F(1.66,3.33) = 0.57 |
| 8. WAY (10 and 100 mg·kg−1) and OT (1 mg·kg−1) | ||
| (i) VEH versus OT | F(1,3) = 217.31*** | F(2.62,7.85) = 6.64* |
| (ii) OT versus WAY (10) + OT | F(1,3) = 58.17** | F(2.54,7.61) = 3.43 |
| (iii) OT versus WAY (100) + OT | F(1,3) = 31.52* | F(2.11,6.34) = 8.49* |
| 9. WAY (10 and 100 mg·kg−1) and AVP (0.1 mg·kg−1) | ||
| (i) VEH versus AVP | F(1,3) = 108.58** | F(2.57,7.70) = 4.63 |
| (ii) AVP versus WAY (10) + AVP | F(1,3) = 2.28 | F(2.54,7.62) = 3.01 |
| (iii) AVP versus WAY (100) + AVP | F(1,3) = 18.28 | F(1.85,5.54) = 2.92 |
Asterisks represent significant differences in heart rate:
*
P < 0.05,
**
P < 0.01 and
***
P < 0.001.
C25, Compound 25; SR, SR49059; VEH, vehicle; WAY, WAY 267,464.